UBS sets a USD 16.00 target for Ultragenyx stock

Published on 10/15/2026 at 19:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 214.00 million, up 28.53 percent from USD 166.50 million. Ultragenyx stock costs EUR 13.46 on October 15, 2026 at 7:44 p.m. CEST.

Analyst target and valuation

UBS initiated Ultragenyx coverage with a USD 16.00 target on October 14, 2026.
Second-quarter revenue reached USD 214.00 million, up 28.53 percent from USD 166.50 million.
Ultragenyx stock costs EUR 13.46 at Lang & Schwarz on October 15, 2026 at 7:44 p.m. CEST.
The next scheduled earnings date is November 3, 2026.

RARE, US90400D1081, Illustration mit AI erstellt.

UBS initiated coverage of Ultragenyx with a Neutral rating and a USD 16.00 price target in a research note dated October 14, 2026, according to Markets Insider. The target is 5.68 percent above the USD 15.14 Nasdaq price available at the same assessment point. The euro quotation was EUR 13.46 at Lang & Schwarz on October 15, 2026 at 7:44 p.m. CEST.

Revenue growth meets a wider loss

Ultragenyx generated USD 214.00 million in revenue for the second quarter of 2026, compared with USD 166.50 million in the same quarter of 2025, a 28.53 percent increase. The company also reported a GAAP net loss of USD 92.00 million for the second quarter of 2026, versus a USD 114.95 million loss a year earlier, according to Markets Insider.

Nasdaq price stays below the yearly high

Ultragenyx stock was at USD 15.14 on Nasdaq on October 15, 2026 at 1:51 p.m. ET, up 1.61 percent from the prior close of USD 14.90. Its intraday range was USD 14.79 to USD 15.27, while trading volume reached 1,543,428 shares against an average of 4,007,621 shares.

The 52-week range was USD 12.73 to USD 39.89 as of October 15, 2026. The current Nasdaq price stood 62.05 percent below the 52-week high and 18.93 percent above the 52-week low. StockAnalysis identifies Ultragenyx as a Nasdaq-listed biotechnology company under ticker RARE.

Valuation and the next reporting date

Ultragenyx had a market capitalization of USD 1.5 billion and a P/E ratio of minus 2.59 as of October 15, 2026. The company does not pay a dividend. StockAnalysis lists November 3, 2026 as the estimated next earnings date, giving investors a defined calendar point after the second-quarter figures.

Comparison with peers

Ultragenyx: P/E -2.59, market capitalization USD 1.5 billion

Sarepta Therapeutics (Nasdaq, USD): plus 5.44 percent, P/E -6.11, market capitalization USD 1.9 billion

BioMarin Pharmaceutical (Nasdaq, USD): plus 2.79 percent, P/E 145.23, market capitalization USD 11.0 billion

Euro quote after the Xetra session

For German-market investors, the Lang & Schwarz quote was EUR 13.46 on October 15, 2026 at 7:44 p.m. CEST. The Nasdaq price was USD 15.14 at 1:51 p.m. ET on the same date, placing the two quotations in separate market and currency contexts.

The further course of trading is shown by the continuously updated real-time quote of Ultragenyx stock.